BL
NAVB

Bolton LP’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bolton LP’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-53
Closed -$88K – 333
2013
Q3 		$88K Buy
+53
New +$3.09K 0.02% 182

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bolton LP's NAVB Position: Q1 2014 in Review

Bolton LP sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2014, closing a stake of 3,870 shares — an estimated $160K sold.

Bolton LP first reported a position in NAVB in Q3 2013 and held it in 2 quarters. The position peaked at $281K in Q3 2013. 83 funds tracked by Wall St. Rank hold NAVB as of Q1 2014.

  • Bolton LP reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2014 after selling out during the quarter.
  • Bolton LP sold 3,870 Navidea Biopharmaceuticals Inc. shares in Q1 2014, an estimated $160K.
  • Bolton LP first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 2 quarters.
  • Bolton LP's Navidea Biopharmaceuticals Inc. position peaked at $281K in Q3 2013.
  • 83 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2014.

Based on Bolton LP's 13F filing for Q1 2014, filed 15 May 2014.